OxSYPan: Oxford Study With Young People on Antidepressants

University of Oxford logo

University of Oxford

Status

Completed

Conditions

Depression

Treatments

Drug: Fluoxetine
Other: Peppermint syrup

Study type

Interventional

Funder types

Other

Identifiers

NCT03436173
12/SC/0030

Details and patient eligibility

About

Fluoxetine is commonly used to treat adolescent depression, but the neural mechanisms underlying antidepressant drugs in the young brain are still poorly understood. This study proposes to investigate the effects of a single dose of fluoxetine on emotional neural processing in a sample of depressed adolescents, using functional Magnetic Resonance Imaging (fMRI).

Full description

Depression is common in adolescence and is associated with a high risk of suicide. Clinically, the presentation of depression in young people is largely similar to the symptoms seen in adulthood, although depressed youth may exhibit increased irritability rather than (or in addition to) low mood. Therefore, irritability is included as a cardinal symptom in the diagnosis of Major Depressive Disorder (MDD) among children and adolescents but not adults (American Psychiatric Association, 2013). Fluoxetine is the antidepressant with the most favourable benefit:risk ratio profile to treat adolescent depression, and is the only medication approved for use to treat this disorder in the United Kingdom (UK). In the United States (US), fluoxetine is also the drug of choice, together with escitalopram. However, our current understanding of the mechanisms underlying antidepressant action in adolescents and young people is poor, despite the pressing need to explain the complex patterns of clinical response to pharmacotherapy in this group. In this randomised, placebo-controlled experimental medicine study, the investigators propose to use fMRI to investigate the early effects of fluoxetine in a sample of depressed adolescents who have been prescribed fluoxetine by their psychiatrist for the treatment of depression. Immediately after being referred to the study team, participants will be randomised to take their first dose of either fluoxetine or placebo within the study, and 6 hours later, they will undergo a neuroimaging scan. Previous research from our group showed that a single dose of fluoxetine reduced the accuracy to detect angry facial expressions in a group of young healthy volunteers, aged 18 to 21 (Capitão et al., 2015). Given the key role of anger in the clinical presentation of adolescent depression, the reduction in anger perception following fluoxetine highlights a potential mechanism through which this antidepressant drug may exert its clinical action. However, this hypothesis remains to be investigated in depressed adolescents. This study therefore proposes to investigate the acute effects of fluoxetine vs. placebo on emotional neural processing, specifically in response to angry faces, in a sample of adolescents with MDD. A secondary aim is to investigate the effects of fluoxetine on emotional regulation, as well as on resting-state functional connectivity. To the extent of the investigators' knowledge, this is the first study to explore the acute neural effects of fluoxetine in depressed adolescents. This design is thought to be of high value as patients will be referred to the study immediately after being prescribed fluoxetine, therefore allowing the investigators to scan them on the day that they take their first dose of 10 mg fluoxetine or placebo, administered within the study. Patients will then start their antidepressant treatment as prescribed and managed by their treating psychiatrist. This unique time window for testing allows the investigation of the effects of fluoxetine using a placebo control, and without the ethical concerns associated with long-term antidepressant drug studies. This single dose design also enables the characterisation of the effects of fluoxetine at a time where changes in mood are not yet apparent. Indeed, the few neuroimaging studies conducted to date with depressed adolescents are limited by the absence of a placebo control and the measurement of neural changes after relatively prolonged treatments (8 weeks). Concurrent changes in symptoms make it difficult to determine whether fluoxetine has a direct effect on relevant neural regions or whether the antidepressant-induced changes in activity are an indirect consequence of mood improvement. The current study design overcomes these constraints. The knowledge attained from this study will hopefully help increase our understanding of the early mechanisms underlying fluoxetine use in depressed adolescents.

Enrollment

32 patients

Sex

All

Ages

13 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Current episode of depression with or without comorbid anxiety and in need of antidepressant medication (as assessed by the Adolescent Psychiatrist);
  • Participant and parent/legal guardian (for participants younger than 16) are willing and able to give informed consent for participation in the study;
  • Male or female, aged 13-18;
  • Sufficiently fluent in English to understand the task and instructions.

Exclusion criteria

  • Current or past psychosis or mania;
  • Current substance misuse;
  • Psychotropic medication usage within the past 6 weeks;
  • Contraindication to fMRI (e.g. metal in body, claustrophobia, pregnancy, etc);
  • Risk of waiting 5-7 days before the initiation of medication assessed as posing serious risk (as assessed by the Adolescent Psychiatrist).

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

32 participants in 2 patient groups, including a placebo group

Fluoxetine
Experimental group
Description:
Fluoxetine 10 mg/2.5 ml
Treatment:
Drug: Fluoxetine
Placebo
Placebo Comparator group
Description:
Peppermint syrup measured to equivalent volume
Treatment:
Other: Peppermint syrup

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems